论文部分内容阅读
目的:分析IPSA联合宫颈中心加量方式在局部晚期宫颈癌腔内联合组织间插植(IC/IS)治疗中剂量学方面优势。方法:选取宫颈癌(Ⅱn B期)经调强放疗45 Gy分25次后局部病灶≥5 cm患者46例，行宫腔管及插植针植入，在CT图像上勾画高危临床靶体积(HR-CTV)、直肠、膀胱、乙状结肠及宫颈加量区宫颈中心(HR-宫颈)，采用IPSA优化。根据宫颈中心是否加量，分成IC/IS＋宫颈中心(HR-宫颈)组(A组)和IC/IS组(B组)，比较A、B组间剂量学差异。n 结果:A组宫腔管驻留时间较B组明显提高(n P<0.001)；宫颈中心的Vn 150%和Vn 200%由原来B组63.94%和30.80%分别提高到91.54%和64.06%；A组Dn 90%及Dn 100%低于B组(n P0.05)。n 结论:IPSA联合宫颈中心加量方式可满足高危临床靶体积Dn 90%受量及危及器官限量，并可提高宫颈中心区剂量。n “,”Objective:To analyze the advantages of IPSA combined with increasing cervical center dose in intracavitary and interstitial brachytherapy (IC/IS) for locally advanced cervical cancer.Methods:A total of 46 stage Ⅱn B cervical cancer patients with, local lesion size≥5 cm after 45 Gy/25f external intensity-modulated radiotherapy (IMRT) were recruited. Uterine tandem and needles were implanted, CT was performed, and then HR-CTV, rectum, bladder, sigmoid colon and the area of cervix increased dose (HR-cervix) were delineated, IPSA was used for optimization. According to whether the dose of HR-cervix was increased or not, all patients were divided into IC/IS+ HR-cervix group (group A) and IC/IS group (group B). The differences in dosimetric parameters were compared between two groups.n Results:The relative uterine tandem dwell time was significantly extended in group A (n P<0.001). In group B, the Vn 150% and Vn 200% volumes of HR-cervix were increased from 63.94% and 30.80% to 91.54% and 64.06%. The Dn 90% and Dn 100% in group A were significantly lower than those in group B (both n P<0.05). There was no statistical difference in organ at risk (OAR) dose.n Conclusion:IPSA combined with increasing cervical center dose can meet the HR-CTV Dn 90% dose requirement, normal tissue dose limits, and can escalate the doses to local areas of the cervix.n